COMPUGEN LTD
Business
COMPUGEN LTD is a clinical-stage therapeutic discovery and development company that uses its AI/ML-powered predictive computational discovery platform, UnigenTM, to identify novel drug targets and advance therapeutics in cancer immunotherapy. Its main products and programs include clinical-stage antibodies and biologics such as COM701 (anti-PVRIG), COM902 (anti-TIGIT), rilvegostomig (PD-1/TIGIT bispecific), GS-0321 (anti-IL-18BP) and returned rights to bapotulimab. The company’s activities are organized around computational target discovery, preclinical research and clinical development, and partnering/licensing arrangements. It conducts global clinical trials and advances products through collaborations, third-party contract manufacturers and licensing to major pharmaceutical partners.
Summary from filing dated 2025-03-04
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | $72.76M |
| Net income | $35.34M |
| Total assets | $156.57M |
| Total liabilities | — |
| Stockholders' equity | $102.73M |
| Operating cash flow | $31.63M |